Skip to main content
Ashkan Emadi, MD, Oncology, Morgantown, WV

Ashkan Emadi MD PhD

Oncology•Morgantown, WV

Hematologic Oncology, Clinical Pharmacology

Professor of Medicine and Pharmacology at University of Maryland School of Medicine; Associate Director for Clinical Research Greenebaum Comprehensive Cancer Center; Director Translational Genomics Laboratory

Join to View Full Profile

  • 1 Medical Center DrMorgantown, WV 26506

  • Phone+1 304-598-4500

  • Fax+1 410-328-6896

Dr. Emadi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Emadi's Full ProfileAlready have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
  • University of Cincinnati Medical Center/College of Medicine
    University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2005 - 2007
  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineInternship, Internal Medicine, 2004 - 2005
  • Illinois Institute of Technology
    Illinois Institute of TechnologyPhD, Organic Chemistry, 2000 - 2004
  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 1999

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2006 - 2026
  • WV State Medical License
    WV State Medical License 2024 - 2026
  • OH State Medical License
    OH State Medical License 2005 - 2007
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    Ashkan Emadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Groundbreaking Study Co-Authored by WVU Cancer Institute Physician Could Lead to Better Treatment for Acute Myeloid Leukemia
    Groundbreaking Study Co-Authored by WVU Cancer Institute Physician Could Lead to Better Treatment for Acute Myeloid LeukemiaNovember 19th, 2024
  • MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)
    MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
  • $50 Million Gift Will Spur Development of Morgantown Cancer Center
    $50 Million Gift Will Spur Development of Morgantown Cancer CenterApril 7th, 2024

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Ashkan Emadi, Dr. Ashkan Emadi, MD, Dr. A Emadi